These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7548701)

  • 41. Pharmacological interventions for treating heart failure in patients with chagas cardiomyopathy.
    Hidalgo R; Martí-Carvajal AJ; Kwong JS; Simancas-Racines D; Nicola S
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009077. PubMed ID: 23152267
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Protocol-guide in clinical experimentation on inotropic drugs].
    Campolo L; Padrini R; Razzolini R; Klugmann S; Chioin R
    G Ital Cardiol; 1985 Jul; 15(7):695-9. PubMed ID: 4076703
    [No Abstract]   [Full Text] [Related]  

  • 43. Treatment of diastolic heart failure.
    Dhir SK
    Mayo Clin Proc; 2002 Mar; 77(3):295-6. PubMed ID: 11888037
    [No Abstract]   [Full Text] [Related]  

  • 44. Strengthening the understanding of the relationship between survival designs and test statistics.
    Ma G; Ganju J
    Pharm Stat; 2010; 9(2):113-24. PubMed ID: 19507135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A note on P-values under group sequential testing and nonproportional hazards.
    Gillen DL; Emerson SS
    Biometrics; 2005 Jun; 61(2):546-51. PubMed ID: 16011703
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strategies for changing the test statistic during a clinical trial.
    Lawrence J
    J Biopharm Stat; 2002 May; 12(2):193-205. PubMed ID: 12413240
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The dilemma of drug development for heart failure: when is the time to initiate large clinical trials?
    Massie BM
    J Card Fail; 2003 Oct; 9(5):347-9. PubMed ID: 14583893
    [No Abstract]   [Full Text] [Related]  

  • 48. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).
    Deswal A; Petersen NJ; Feldman AM; Young JB; White BG; Mann DL
    Circulation; 2001 Apr; 103(16):2055-9. PubMed ID: 11319194
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Whither Withering's Legacy? Digoxin's role in our contemporary pharmacopeia for heart failure.
    Young JB
    J Am Coll Cardiol; 2005 Aug; 46(3):505-7. PubMed ID: 16053965
    [No Abstract]   [Full Text] [Related]  

  • 50. Quinolinone derivatives in the management of congestive heart failure.
    Feldman AM; Strobeck JE
    Coron Artery Dis; 1994 Feb; 5(2):107-11. PubMed ID: 8180742
    [No Abstract]   [Full Text] [Related]  

  • 51. Vesnarinone: a new inotropic agent for treating congestive heart failure.
    Cavusoglu E; Frishman WH; Klapholz M
    J Card Fail; 1995 Jun; 1(3):249-57. PubMed ID: 9420657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
    Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
    Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is there a role for positive inotropic agents in congestive heart failure: focus on mortality.
    Amidon TM; Parmley WW
    Clin Cardiol; 1994 Dec; 17(12):641-7. PubMed ID: 7867235
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy evaluation for monotherapies in two-by-two factorial trials.
    Hung HM; Chi GY; O'Neill RT
    Biometrics; 1995 Dec; 51(4):1483-93. PubMed ID: 8589235
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The search for the ideal positive inotropic agent.
    Packer M
    N Engl J Med; 1993 Jul; 329(3):201-2. PubMed ID: 8515793
    [No Abstract]   [Full Text] [Related]  

  • 58. [Learning from mistakes. Considerations on unsuccessful clinical trials of pharmacological therapies in acute heart failure].
    Frigerio M
    G Ital Cardiol (Rome); 2014 Jan; 15(1):13-8. PubMed ID: 24503729
    [No Abstract]   [Full Text] [Related]  

  • 59. Case series analysis for censored, perturbed, or curtailed post-event exposures.
    Farrington CP; Whitaker HJ; Hocine MN
    Biostatistics; 2009 Jan; 10(1):3-16. PubMed ID: 18499654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monitoring a randomized clinical trial for futility: the north-Norwegian lidocaine intervention trial.
    Berntsen RF; Rasmussen K; Bjørnstad JF
    Stat Med; 1991 Mar; 10(3):405-12. PubMed ID: 2028124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.